title: Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
abstract: The clonality of peripheral blood cells was assessed in eight female patients with myelodysplastic syndrome (MDS) by means of the human androgen receptor gene-based assay (HUMARA). The patients were in complete remission for a median follow-up time of 83 months after intensive chemotherapy. X-chromosome inactivation patterns (XCIPs) indicated polyclonal haemopoiesis in five patients. Two patients had skewed lyonization (i.e. unbalanced XCIPs in both granulocytes and T cells) and one patient presented monoclonal granulocytes together with polyclonal T cells. We conclude that long-term remission in MDS following intensive chemotherapy is usually associated with polyclonal haemopoiesis.
authors.affiliation: Department of Haematology, Heinrich-Heine-University, Düsseldorf, Germany. alvesai@uni-duesseldorf.de
authors.forename: M
authors.initials: M
authors.lastname: Aivado
authors.forename: A
authors.initials: A
authors.lastname: Rong
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: N
authors.initials: N
authors.lastname: Gattermann
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
authors.forename: C
authors.initials: C
authors.lastname: Rieth
authors.forename: R
authors.initials: R
authors.lastname: Haas
authors.forename: C
authors.initials: C
authors.lastname: Aul
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004303:Dosage Compensation, Genetic; D005260:Female; D005500:Follow-Up Studies; D006410:Hematopoiesis; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D012189:Retrospective Studies; D013866:Thioguanine / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D003561:Cytarabine; D003520:Cyclophosphamide; D008942:Mitoxantrone; D013866:Thioguanine; D015255:Idarubicin; D003630:Daunorubicin